CalciMedica Secures Credit Facility for Up to $32.5 Million

Provided By PR Newswire

Last update: Mar 5, 2025

$10 million funded at close extends cash runway into mid-2026

LA JOLLA, Calif., March 5, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that the Company has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $32.5 million. Proceeds from the facility are intended to support the continued development of the Company's product pipeline.